Zylox-Tonbridge Reports 2024 Annual Results: First Full-Year Profit Surpassing USD 14 Million

Zylox-Tonbridge Medical Technology Co., Ltd. has announced its 2024 annual results, reflecting the company's commitment to its mission of "Innovation for Quality Life" and its focus on advancing medical technology. In 2024, Zylox-Tonbridge achieved its first full year of profitability, reporting revenue of USD 109.4 million, marking a 48.3% increase year-on-year, and a net profit exceeding USD 14 million. This growth was driven by economies of scale and strategic involvement in centralized procurement.

The company actively participated in centralized procurement, successfully securing multiple bids with its strong product portfolio, which includes the SilverSnake Intracranial Support Catheter and the ZYLOX Penguin Peripheral Venous Stent System, highlighting its focus on vascular intervention products. Zylox-Tonbridge is also expanding its global presence, with 20 products commercialized across 24 countries and regions, including Germany, Italy, Argentina, Brazil, and the UAE. This expansion contributed to overseas revenue of USD 3.2 million in 2024, reflecting a four-year compound annual growth rate of 87%.